SYMBICORT 160/4.5 for the maintenance treatment of COPD

The efficacy of SYMBICORT

FAST CONTROL

Majority of FEV1 improvement at 5 minutes each time in a subset of SUN Study patients taking SYMBICORT 160/4.5 (n=121)2

SUSTAINED EFFECT

Significant lung function improvement with continuous control, as demonstrated over 12 months in the SUN Study (n=494)1,2

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection

In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3

SYMBICORT 160/4.5 for the maintenance treatment of COPD

The efficacy of SYMBICORT

FAST CONTROL

Majority of FEV1 improvement at 5 minutes each time in a subset of SUN Study patients taking SYMBICORT 160/4.5 (n=121)2

SUSTAINED EFFECT

Significant lung function improvement with continuous control, as demonstrated over 12 months in the SUN Study (n=494)1,2

SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection

In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV1 improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment.1-3

Click on the links below to view clinical data about the efficacy and safety of SYMBICORT 160/4.5 in the treatment of COPD: